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Aim of this study was to review the institutional experience of solid-pseudopapillary tumors of the pancreas with particular
attention to the problems of preoperative diagnosis and treatment. From 1997 to 2013, SPT was diagnosed in 18 patients among 451
pancreatic cystic neoplasms (3.7%). All patients underwent preoperative abdominal ultrasound, computed assisted tomography,
and tumor markers (CEA and CA 19-9) determinations. In some instances, magnetic resonance, positron emission tomography,
and endoscopic ultrasound with aspiration cytology were performed. There were two males and 16 females. Serum CA 19-9 was
slightly elevated in one case. Preoperative diagnosis was neuroendocrine tumor (𝑛 = 2), mucinous tumor (𝑛 = 2), and SPT (𝑛 = 14).
Two patients underwent previous operation before referral to our department: one explorative laparotomy and one enucleation of
SPT resulting in surgical margins involvement. All patients underwent pancreatic resection associated with portal vein resection
(𝑛 = 1) or liver metastases (𝑛 = 1). One patient died of metastatic disease, 77 months after operation, and 17 are alive and free with
a median survival time of 81.5 months (range 36–228 months). Most of SPT can be diagnosed by CT or MRI, and the role of other
diagnostic tools is very limited. We lack sufficient information regarding clinicopathologic features predicting prognosis. Caution
is needed when performing limited resection, and long and careful follow-up is required for all patients after surgery.
1. Introduction
Solid-pseudopapillary tumor (SPT) is a distinct variety
among cystic neoplasms of the pancreas. Although rare,
this type of tumor is increasingly seen in clinical practice
because of widespread availability of imaging modalities
and better awareness of the disease. In a review of English
literature from 1933 to 2003, a total of 718 SPTs were collected,
including pediatric cases [1]; in a recent review of Law et al.
in 2014 [2], a total of 2744 patients with SPT were identified,
of whom 2410 were observed from 2000 to 2012. Solid-
pseudopapillary tumor is generally considered an indolent
lesionwith lowmalignant potential; it occursmost frequently
in young women. Favorable prognosis after surgical resection
has been invariably reported. However, some cases of locally
infiltrating or metastatic variety, or recurrences after surgery,
have been described in a significant percentage of 10–15% of
patients [3]. Long-term survival is reported even formetastat-
ic disease, but some patients will eventually die for disease’s
progression, suggesting a widely variable and not clearly
elucidated biology of the tumor.
We report our experience of SPTs with particular atten-
tion to identify the problems in differential diagnosis, the
clinicopathological features predicting behaviour, and the
treatment and outcome after tumor’s resection.
2. Patients and Methods
We retrospectively reviewed the patients who underwent sur-
gical resection of SPT of the pancreas from the prospectively
recorded database, between January 1997 andDecember 2013.
We evaluated patients’ demographic features, clinical pre-
sentation, imaging findings, surgical procedures, pathologic
aspects, perioperative outcome, follow-up, and survival. All
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Table 1: Clinicopathologic features of patients with pancreatic SPT.
Pts Sex Age Site Size Treatment Follow-up (months)
(1) Female 54 Tail 4.0 DP A,NED (228)
(2) Female 13 Body 4.0 CP A,NED (198)
(3) Female 32 Tail 7.0 DP A,NED (192)
(4) Female 31 Tail 14.0 DP A,NED (180)
(5) Female 20 Tail 10.0 DP A,NED (156)
(6) Female 14 Tail 10.0 DP A,NED (132)
(7) Female 38 Body 3.0 DP A,NED (96)
(8) Male 59 Tail 11.0 DP A,NED (94)
(9) Female 40 Body 2.0 CP A,NED (84)
(10) Female 21 Head 8.0 PPPD A,NED (79)
(11) Female 13 Head 3.0 PPPD A,NED (77)
(12) Female 49 Head-body 10.0 TP + VR DEAD (77)
(13) Female 38 Tail 4.0 DPSP A,NED (74)
(14) Male 75 Tail 4.5 DP A,NED (72)
(15) Female 30 Tail 10.0 DP A,NED (61)
(16) Female 24 Body 7.0 DP A,NED (50)
(17) Female 14 Head 3.0 PPPD A,NED (48)
(18) Female 35 Tail 4.5 DP A,NED (36)
DP = distal pancreatectomy; CP = central pancreatectomy; TP = total pancreatectomy; VR = venous resection; PPPD = pylorus-preserving pancreaticoduo-
denectomy; A = alive; NED = no evidence of disease; DPSP = distal pancreatectomy spleen-preserving.
patients preoperatively underwent serum carcinoembryonic
antigen CEA and CA 19-9 examination, abdominal ultra-
sonography (US), and computed assisted tomography (CT).
In some instances, magnetic resonance imaging (MRI), 18-
FDG positron emission tomography (PET/CT), and endo-
scopic ultrasound (EUS) with fine-needle aspiration (FNA)
were also performed. Pathologically, SPTs were classified as
malignant if it showed extrapancreatic invasion, perineural
or vascular invasion, pancreatic parenchyma invasion [4], or
distantmetastases. Follow-up included physical examination,
serum tumor markers, and US and/or CT or MRI every 6
months for the first 5 years and then every year. PET/CT was
performed when clinically suggested. The median follow-up
period was 84 months (range 36–228 months).
3. Results
In the study period, 451 patients with cystic tumors of
the pancreas were observed; among these, 18 (3.7%) were
histologically proven to have SPT of the pancreas (Table 1).
There were 16 females and 2 males, with a mean age of 34.2
years (range 13–75): both male patients were older compared
to females. Patients presented abdominal pain or discomfort
(𝑛 = 9) and palpable mass (𝑛 = 6); three patients were
asymptomatic.The tumor averaged 7.0 cm in diameter (range
2–14 cm) and was located in the body and/or tail of the
pancreas in 13 patients, in the head in 3 patients, and in the
neck in two patients. Three patients had surgery in other
hospitals before referral to our department: one patient had
cystogastrostomy for an incorrect diagnosis of pancreatic
pseudocyst; one had exploratory laparotomy and biopsy
for a locally advanced pancreatic mass involving portal-
mesenteric vein; and one young patient had enucleation of
Figure 1: Computed tomography of the abdomen showing a large
cystic mass with solid components in the body-tail of the pancreas
(case number 13).
3 cm pancreatic head mass that showed surgical margins
involvement at pathologic examination. Only one patient
showed high serum CA 19-9 levels (92U/mL; normal value <
37U/mL). Preoperative radiological investigation included
abdominal US and CT in all patients (Figure 1), MRI in
6 patients, and EUS + fine-needle aspiration in 5. Two
patients had a correct cytologic diagnosis of SPT; 2 patients
had a suggested diagnosis of neuroendocrine tumor (but
with radiologic findings suggestive for SPT) and in one
cytology was nondiagnostic. Ten patients underwent 18-FDG
positron emission tomography (PET); in 7 patients there
was a pathologic uptake of the radiotracer (mean SUV 8.8,
range 2.6–24.0) (Figure 2). Two patients underwent 111-In-
Octreoscan without pathologic uptake of the radiotracer. So,
preoperative diagnosis was neuroendocrine tumor (𝑛 = 2),
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Figure 2: Positron emission tomographywith CT acquisition (PET/CT) of the abdomen: axial (a) and coronal image (b) showing a pathologic
uptake of FDG in a well-circumscribed, round mass in the tail of the pancreas (case number 15).
mucinous tumor (𝑛 = 2), and SPT (𝑛 = 14). Twelve
patients underwent distal pancreatectomy (4 with spleen
preservation and 2 with laparoscopic approach), 3 pylorus-
preserving pancreaticoduodenectomy, 2 central pancreatec-
tomy and 1 total pancreatectomy. One patient had associated
resection of involved portal vein segment with jugular vein
reconstruction. The invasion of portal vein was confirmed
at pathological examination but no adjuvant chemotherapy
was scheduled since the patient refused any other treatment.
Another patient had synchronous resection of two small
hepatic metastases. The patient reoperated after enucleation
of pancreatic head lesion and underwent pancreaticoduo-
denectomy; pathological examination showed residual SPT.
All 18 patients had R0 resection, and there were no
surgical mortalities. Postoperative complications occurred in
5 patients (28%); according to the International Study Group
on Pancreatic Fistula (ISGPF) [5], one patient had Grade A,
and four patients had Grade B pancreatic fistula, the latter
requiring drainage under radiologic guidance.
Pathologic examination showed cellular atypia in 3
patients (numbers 5, 10, and 17), vascular invasion in 4
(numbers 5, 10, 12, and 13), perineural invasion in 4 (nr 9,
10, 16, 17), capsular invasion in 4 (numbers 3, 5, 9, and 10),
and lymph node and liver metastases only in one patient
(number 10). All but one patient (number 8) showed Mib
1 ≤ 1 (Table 2). B-catenin was always expressed. (Figure 3).
One patient (number 10) had postoperative adjuvant therapy
(gemcitabine regimen).
One patient died 77 months after operation, 45 months
after tumor recurrence (liver metastases); the remaining
patients are alive and well, free of disease with a median sur-
vival time of 81.5 months (range 36–228 months) (Figure 4).
4. Discussion
Solid-pseudopapillary tumor is a very rare neoplasm of the
pancreas, accounting for only 1-2% of all exocrine pancreatic
tumors [3]; in our experience we observed 18 SPTs among
Table 2: Clinicopathological features of Benign andMalignant SPT.
Benign Malignant
(𝑛 = 10) (𝑛 = 8)
Age
<40 7 6
≥40 3 2
Sex
F 8 8
M 2 0
Tumor size
<5 6 3
≥5 4 5
Tumor localization
Head-neck 1 3
Body-tail 9 5
R0 resection 10 8
Pancreatic parenchyma/capsular invasion 0 4
Vascular invasion 0 4
Perineural invasion 0 4
Cellular atypia 0 3
Metastases 0 1
Mib1
<1% 9 8
≥1% 1 0
Ki-67
<4% 10 8
≥4% 0 0
a total of 451 (3.7%) cystic tumors of the pancreas from 1997 to
2013. In the last decade, there has been a significant increase
in the number of SPTs published in the English literature
[2], confirming the increasing interest toward this unique
neoplasm. Most of our patients were female, at young age
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Figure 3: Hematoxylin and eosin stain (H&E, 100x) of SPT showing normal pancreas on the upper left side and neoplastic cells in the lower
right side (a) and immunohistochemical 𝛽-catenin slide (100x) showing the different pattern of staining in normal pancreas (cytoplasmic)
and in neoplastic pancreas (nuclear) (b).
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Figure 4: Kaplan-Meier survival curve of patients who underwent
pancreatic resection of SPT.
(mean 34.2 years, range 13–75). Only two patients weremales,
older than females, both are alive and free of disease for 48
and 84 months, respectively. It has been reported that male
patients have distinct patterns of onset and aggressiveness
compared with female patients. Machado et al. [6] observed
that SPTs inmale patients were more aggressive than those in
female patients, and they should be managed more radically.
On the contrary, Cai et al. [7]. collected 16 male patients with
SPTs, and observed thatmaleswere older than female patients
and had a favorable outcome after surgery, with no recurrence
or death of disease in the follow-up.
Clinical presentation of SPTs is not specific. The most
frequent symptoms in our series were abdominal pain or
discomfort, followed by abdominal mass; 2 patients were
asymptomatic. These findings are well in accordance with
previous reports [7–9]. Preoperative diagnosis of SPTs is
generally made by CT or MRI imaging. Typically the tumor
shows a large, well circumscribed, heterogeneous mass with
varying solid and cystic components, generally demarcated
by a peripheral capsule and occasional calcifications [10, 11].
These findings, together with other clinical findings, such as
age and sex, may be sufficient for a correct diagnosis, as in
more half of our patients (Figure 1). Problems in differential
diagnosis occur in the presence of small, solid lesions, or
in large, unilocular cyst, or in male patients. Recently, EUS
with FNA has been advocated as useful diagnostic tool also
in SPTs. The diagnostic accuracy of EUS-FNA for SPT was
found to be 75% in a multicentric experience of Jani et al.
[12] in 2008. More recently, Law et al. [13] reported that
the addition of EUS-FNA to a preoperative work-up of
SPT significantly increased the diagnostic yield to 82.4%.
In our experience, 5 patients underwent preoperative EUS-
FNA: only 2 patients had a correct diagnosis of SPT. One
patient had inconclusive results, and two had a suspected
diagnosis of neuroendocrine tumor; this finding led us to
perform octreotide scintigraphy and serumhormonal studies
(both negative). However, CT and MR findings of these two
patients were compatible with the diagnosis of SPT. In one
patient EUS-FNAwas complicated bymild acute pancreatitis.
Recently, Virgilio et al. [14] reported a case of rupture of
SPT following EUS-FNA. So the real utility of EUS in the
diagnostic work-up of SPT is unclear and it appears indicated
in very selected, doubtful cases.
Positron emission tomography with 18-FDG has an
emerging role in the diagnosis and staging of pancreatic
neoplasms, including cystic tumors [15]. The role of PET in
these rare tumors is obviously not well defined. We perform
preoperative PET in 10 patients: 7 showed a pathologic
uptake in the tumor’s area (Figure 2), while three patients
did not. However, high accumulation of FDG in the tumor
does not correlate with more aggressive behaviour, clinical
characteristics, or histopathological features of malignancy,
since all but one of these patients are alive without evidence of
tumor’s relapse. Dong et al. [16] studied 8 patients with SPTs
who underwent preoperative PET; they found a relationship
between standard uptake value (SUVmax) and histological
malignancy of the tumor. However, all patients were alive
without recurrence after surgery, although follow-upwas very
short.
Recently, Kang et al. [17] reported a large experience of 37
SPTs studied with 18-FDG PET; the pattern of FDG uptake
in SPTs was not associated with histopathologic features sug-
gestive ofmalignant potential.Moreover, SUVmax apparently
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increased according to the degree of Ki-67 expression, but
without statistical significance.They concluded that the clini-
cal usefulness of PET in SPTs needs to be further investigated.
At the moment, it appears that 18-FDG PET does not have a
substantial role in the diagnosis of SPTs.
In our series, only one patient presented with preopera-
tive slight increase of serum CA 19-9, so the role of tumor
markers in both the diagnosis and monitoring of the disease
appears very limited.
SPT is generally considered as a tumor with low malig-
nant potential. Although resection of the tumor provides a
5-year survival rate more than 95% [18], local recurrence or
distant metastases can occur.Moreover aminority of patients
show locally advanced or metastatic disease at their initial
presentation. One patient presented with malignant locally
advanced tumor, invading the portal vein. Total pancreate-
ctomy with portal vein resection and reconstruction with
jugular vein graft was performed, but the tumor recurred
in the liver and the patient died 77 months after surgery.
Locally infiltrative solid-pseudopapillary tumors of the pan-
creas occur infrequently; in 2008 we collected from English
literature, a total of 20 patients with locally malignant SPT:
10 patients had portal vein or mesenteric vessels involvement
(associated with liver metastases in two cases) and 10 had
invasion of other organs (colon, spleen, kidney, adrenal gland,
and omentum) [3].
A recent case series [19] of 131 consecutive resections for
SPT has been published, showing only one case of metastatic
disease at presentation and two cases of recurrence after
resection of primary SPT. In all cases, capsular and/or pancre-
atic parenchyma invasion were found. No adjuvant or neoad-
juvant chemotherapy has been administered. One patient
eventually died because of disease progression 56 months
after distal pancreatectomy. Cheng et al. [20] reported their
experience of 8 patients with SPT infiltrating the portal-
mesenteric vein, who underwent pancreatectomy associated
with vascular resection. All but one patient were alive and free
of disease after a median follow-up period of 67.5 months.
One patient who underwent R1 resection died of liver
recurrence 54 months after operation. So vascular invasion,
although uncommon, does occur; vascular resection and
reconstruction is warrantedwhenever possible, because long-
term survival is not infrequent even in locally advanced
disease.
Some reports found that a high Ki-67 mitotic index
occurred more frequently in patients with malignant SPT
and seems to be associated with a shorter survival [21–24].
Yang et al. [25] found that a Ki-67 ≥ 4% was significantly
associated (𝑝 < 0.001) with recurrence. In our experience
neither highMib 1 norKi-67≥ 4%was associatedwith clinical
or histopathological features of malignancy.
Recently, there is increasing interest in less aggressive
surgical procedures for benign or border-line neoplasms of
the pancreas, in order to preserve pancreatic function. So
limited resection (i.e., enucleation, central pancreatectomy,
spleen preservation, etc.) has been advocated also for SPTs
[26]. However, one of our patients underwent pancreatico-
duodenectomy for a previously enucleated SPT of the head of
the pancreas that showed margin involvement at pathologic
examination.
Recurrence after apparently radical resection of SPT is
well reported: metastasis either at the time of presentation
or, less commonly, some years after resection of the primary
tumor develops in less than 15% of cases, and the liver is the
most common site [18, 26].
One of our patients presented with synchronous liver
metastases which were removed together with pancreatico-
duodenectomy. Although there is no evidence of efficient
chemotherapeutic drugs, adjuvant therapy with gemcitabine
was performed, and the patient is alive, without recurrence,
more than 6 years after surgery.
Resection of livermetastases is possible if the involvement
of the liver is limited; survival after metastasis excision is
good because of the indolent nature of the disease, and it
appears that the 5-year survival is not significantly altered
even in the presence of metastatic disease [18, 27]. Only
occasional death from tumor, usually after many years, has
been reported. Our experience confirms that, at present,
there are no established clinical or histological criteria to
predict the biological behaviour of SPT. While invasion of
blood vessels, perineural infiltration, invasion of adjacent
structures, and elevated mitotic rate are suggested to be
associated with metastases and recurrence in some reports
[25, 28, 29], they appear to be not related to prognosis in other
experience [30], and the absence of these features does not
preclude malignant behaviour [22], so long-term follow-up
is warranted in all patients [31].
The utility of chemotherapy and radiotherapy for patients
with SPT is substantially unknown, although there are some
anecdotal reports of benefit [32–36]. Kang et al. [37] per-
formed in vitro adenosine triphosphate based chemotherapy
response assay in five resected SPT of the pancreas; cisplatin
was shown to be the most effective single-chemotherapeutic
agent. This finding has been reported in some previous
experiences [38, 39] but not confirmed in others [40].
The limited number of reported cases explains the lack of
standard treatment, and thus chemotherapeutic agents used
are substantially experimental.
5. Conclusions
Solid-pseudopapillary tumor of the pancreas is an enigmatic
tumor, mostly presenting with benign course or, less fre-
quently, with aggressive behaviour or relapse after resection.
Preoperative diagnosis is substantially made by CT orMRI in
most cases. Because of its rarity, we lack sufficient information
regarding clinicopathologic features predicting prognosis,
and the role of radiochemotherapy in unresectable disease
is clearly unknown. At moment, the biologic behaviour of
SPT is unpredictable, so surgery remains the only chance of
treatment even in locally or metastatic presentation. Long
and careful follow-up is recommended after resection for all
patients.
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